Business Description
Kaken Pharmaceutical Co Ltd
ISIN : JP3207000005
Share Class Description:
KKPCF: Ordinary SharesTotal Employee Number:
1,297Description
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 13.17 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | 0.68 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 4.82 | |||||
Beneish M-Score | -1.97 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.4 | |||||
3-Year EBITDA Growth Rate | -15.7 | |||||
3-Year Book Growth Rate | 2.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 27.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 3.09 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
9-Day RSI | 59.01 | |||||
14-Day RSI | 60.56 | |||||
12-1 Month Momentum % | -7.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.52 | |||||
Quick Ratio | 3.6 | |||||
Cash Ratio | 2.44 | |||||
Days Inventory | 188.93 | |||||
Days Sales Outstanding | 102.69 | |||||
Days Payable | 74.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Dividend Growth Rate | 8.2 | |||||
3-Year Average Share Buyback Ratio | -0.4 | |||||
Shareholder Yield % | 6.52 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 52.02 | |||||
Operating Margin % | -1.17 | |||||
Net Margin % | 2.79 | |||||
EBITDA Margin % | 7.39 | |||||
FCF Margin % | -20.49 | |||||
OCF Margin % | -13.75 | |||||
ROE % | 1.45 | |||||
ROA % | 1.19 | |||||
ROIC % | -0.74 | |||||
3-Year ROIIC % | -19.29 | |||||
ROC (Joel Greenblatt) % | 4.55 | |||||
ROCE % | 1.51 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 68.23 | |||||
Forward PE Ratio | 35.67 | |||||
Shiller PE Ratio | 10.42 | |||||
PS Ratio | 1.91 | |||||
PB Ratio | 0.99 | |||||
Price-to-Tangible-Book | 1.19 | |||||
EV-to-EBIT | 42.12 | |||||
EV-to-EBITDA | 17.48 | |||||
EV-to-Revenue | 1.29 | |||||
EV-to-FCF | -6.02 | |||||
Price-to-GF-Value | 1.02 | |||||
Price-to-Projected-FCF | 0.71 | |||||
Price-to-Median-PS-Value | 0.89 | |||||
| Price-to-Net-Current-Asset-Value | 2.3 | |||||
| Price-to-Net-Cash | 7.26 | |||||
Earnings Yield (Greenblatt) % | 2.37 | |||||
FCF Yield % | -11.29 | |||||
Forward Rate of Return (Yacktman) % | -9.67 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:KKPCF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kaken Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 507.608 | ||
| EPS (TTM) ($) | 0.371 | ||
| Beta | -0.2598 | ||
| 3-Year Sharpe Ratio | -0.24 | ||
| 3-Year Sortino Ratio | -0.34 | ||
| Volatility % | 18.78 | ||
| 14-Day RSI | 60.56 | ||
| 14-Day ATR ($) | 0.000034 | ||
| 20-Day SMA ($) | 26 | ||
| 12-1 Month Momentum % | -7.45 | ||
| 52-Week Range ($) | 23.65 - 28.121 | ||
| Shares Outstanding (Mil) | 37.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kaken Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kaken Pharmaceutical Co Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| JPY 95.000000 Cash Dividend | 2026-09-30 | In 71 days | ||
| JPY 95.000000 Cash Dividend | 2026-03-31 | 26.00 (+0.00%) | ||
| JPY 95.000000 Cash Dividend | 2025-09-29 | 28.09 (+0.00%) | ||
| JPY 75.000000 Cash Dividend | 2025-03-28 | 26.31 (+0.00%) | ||
| JPY 40.000000 Cash Dividend | 2024-09-27 | 28.00 (+0.00%) | ||
| JPY 75.000000 Cash Dividend | 2024-09-27 | 28.00 (+0.00%) | ||
| 0.5:1 Stock Split | 2015-09-28 | -- |
Show
Entries
Kaken Pharmaceutical Co Ltd Frequently Asked Questions
What is Kaken Pharmaceutical Co Ltd(KKPCF)'s stock price today?
The current price of KKPCF is $26.00. The 52 week high of KKPCF is $28.12 and 52 week low is $23.65.
When is next earnings date of Kaken Pharmaceutical Co Ltd(KKPCF)?
The next earnings date of Kaken Pharmaceutical Co Ltd(KKPCF) is .
Does Kaken Pharmaceutical Co Ltd(KKPCF) pay dividends? If so, how much?
Kaken Pharmaceutical Co Ltd(KKPCF) does not pay dividend.
Guru Commentaries on OTCPK:KKPCF
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Kaken Pharmaceutical Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers